FarmaMondo receives Marketing Authorisation for Qarziba® (dinutuximab beta) for infants with High Risk Neuroblastoma

The FarmaMondo Group receives Marketing Authorization for Qarziba® (dinutuximab beta) for infants with High-Risk Neuroblastoma.

Qarziba® is an anti-GD2 monoclonal antibody that has shown to improve significantly the event-free and overall survival in children with high-risk neuroblastoma, with an acceptable safety profile. Qarziba® has been approved on May 2017 by the EU medicines agency (EMA) for this indication.

Since 2017 FarmaMondo exclusively manage the access to Qarziba® in more than 50 countries through a combined model of a Managed Access Programme commercialization. This Marketing Authorisation is a pivotal milestone for the Group and we would like to thank all teams for the extraordinary effort and resilience to have make this possible for the benefit of these young patients.

This achievement reinforces once again our strategy and its recognition by the industry stakeholders. We are proud to have gained the trust of EUSA and Recordati, who entrust us with the responsibility of becoming their marketing authorisation holder in specific markets.


About FarmaMondo

FarmaMondo is a fast-growing Swiss group dedicated to providing Biopharma, healthcare professionals and their patients around the world with greater access to medicines, and in the process increasing the value of a pharmaceutical product by extending and expanding its lifecycle.

The Group offers high value market access and specialty distribution services, through a unique infrastructure and geographical footprint, targeted to enable patient access to Specialty Medicines in key Emerging Markets through a combined approach of Named Patient access and full commercialization after market authorisation.

For more information about FarmaMondo please visit:


About EUSA Pharma and Recordati

EUSA Pharma is a world-class pharmaceutical company with a portfolio in rare and niche oncology products. The company has extensive commercial operations in the EMEA and United States, alongside a presence in other international markets.

On 16th March 2022, Recordati completed the acquisition of EUSA Pharma. Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals.

For more information about EUSA Pharma and Recordati, please visit and